70th Tom D. Rowe Annual Pharmacy Lecture

Speaker
Susan L. Davis, PharmD, FIDP
Clinical Professor
Wayne State University
Detroit, MI

ACPE Universal Activity Number 0112-9999-21-417-L04-P
1.0 contact hour (0.1 CEU)
Knowledge-based

Needs Assessment
By the time of this year’s Annual Pharmacy Lectures, we will have lived with the COVID-19 pandemic for more than 18 months.  Although scientists had warned of the possibility of a global coronavirus outbreak for decades, we were caught largely by surprise, with no readily available tests, treatments, or vaccines.  As we look back, what went right?  What went wrong?  Which treatments lived up to their promise, and which didn’t?  Where are we now, with vaccines readily available?  And perhaps most important, where are we headed?  When does this pandemic “end”… and when might the next one begin?

Learning Objectives
At the completion of this activity, pharmacists will be able to:

1. Recall important milestones, successes, and setbacks in the timeline of the COVID-19 pandemic.
2. Discuss current evidence-based guidelines for treatment and prevention of COVID-19.
3. Identify proposed treatments for COVID-19 that did not live up to their promise.
4. Discuss opportunities for pharmacy professionals in public health response and preparation for future emerging diseases.

Speaker
Keith Yoshizuka, PharmD, MBA, JD, FCSHP
Assistant Dean for Administration and Chair of Social, Behavioral and Administrative Sciences
Touro University California College of Pharmacy
Vallejo, CA

ACPE Universal Activity Number 0112-9999-21-418-L03-P
1.0 contact hour (0.1 CEU)
Knowledge-based

Needs Assessment
The practice of pharmacy is subject to laws: rules that specify what must be done, establish what cannot be done, or authorize an array of options regarding what actions are permissible.  When an array of options is available, how can pharmacists decide on the best option?  Similarly, how should pharmacists approach situations that present conflicts between moral duty and obligations – situations that have no one “right” answer?  Through a series of case examples, pharmacists will learn to navigate the challenges of legal and ethical dilemmas by identifying, analyzing, and prioritizing the principles involved.

Learning Objectives
At the completion of this activity, pharmacists will be able to:

1. Identify situations in which an action may be legal but still present an ethical dilemma.
2. Define the four basic principles of biomedical ethics.
3. Recognize ethical dilemmas that may have arisen during the COVID-19 pandemic.

Speaker
Sergey Rekhtman, MD, PharmD, MPH, FAAD
Assistant Professor, Department of Dermatology
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
New Hyde Park, NY

ACPE Universal Activity Number 0112-9999-21-419-L04-P
1.0 contact hour (0.1 CEU)
Knowledge-based

Needs Assessment
In the nearly 20 years since etanercept (Enbrel) was approved for the treatment of psoriatic arthritis, the therapeutic armamentarium for skin diseases has grown to include 11 biologics for psoriasis and one biologic each for atopic dermatitis, hidradenitis suppurativa, chronic idiopathic urticaria, and pemphigus vulgaris.  These medications are advertised heavily to consumers, and dozens more are in clinical development.  How have these therapies changed the treatment of psoriasis and other skin conditions?  What are the differences among agents that influence patient selection and outcomes?  This session will provide an overview of this rapidly expanding category.

Learning Objectives
At the completion of this activity, pharmacists will be able to:

1. Identify the developments in the pathophysiology of psoriasis (and related conditions) that paved the way for treatment with biologic agents.
2. Discuss how psoriasis was treated, and the expected outcomes of treatment, before and after the advent of biologic agents.
3. Recognize important differences among the biologic agents currently approved for the treatment of psoriasis.
4. List factors that influence the decision to select a specific biologic agent for a particular patient.

Speaker
Gigi Davidson, BSPharm, DICVP
Chief Executive Officer
VetPharm Consulting, LLC
Pittsboro, NC

ACPE Universal Activity Number 0112-9999-21-431-L04-P
1.0 contact hour (0.1 CEU)
Knowledge-based

Needs Assessment
Approximately half of American households own pets, sharing their homes with an estimated 77 million dogs and 54 million cats.  Drug therapy for dogs and cats is on the rise, with an increasing number of prescriptions filled by pharmacists.  In two recent surveys, 75% of the practicing pharmacists who responded indicated that they dispense prescriptions to non-human patients.  But despite the fact that many “human” drugs are used to treat animals, animals are not furry versions of humans; there are sometimes surprising differences in pharmacokinetics and pharmacodynamics, with important implications for medications, doses, and dosage forms.  This session will provide an overview of the human drugs and compounding excipients most likely to cause problems if administered to dogs and cats and provide answers to frequently asked questions. A bibliography of veterinary drug information resources and veterinary pharmacy professional organizations will also be reviewed.

Learning Objectives
At the completion of this activity, pharmacists will be able to:

1. Discuss important anatomical considerations that influence drug therapy in cats and dogs.
2. Explain how species-specific physiological adaptations affect drug disposition in cats and dogs.
3. Identify veterinary drug information resources and veterinary pharmacy professional organizations.

Speaker
Hanna Phan, PharmD, FCCP, FPPA
Clinical Associate Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan

ACPE Universal Activity Number 0112-9999-21-432-L01-P
1.0 contact hour (0.1 CEU)
Knowledge-based

Needs Assessment
The landscape in cystic fibrosis (CF) care has changed markedly in recent years.  Historically, treatment options for patients with CF have been mainly supportive, addressing characteristic pulmonary and gastrointestinal problems such as thick mucus, chronic lung infections, failure to thrive, and pancreatic insufficiency.  With the identification of the cystic fibrosis transmembrane conductance regulator (CFTR) gene and introduction of CFTR modulator therapies, the basic CF cellular defect now can be targeted in approximately 90% of patients.  What does the management of cystic fibrosis look like in this new era of disease-modifying therapy?   What about the other 10% of patients — and the dazzling possibility of a future cure?  This session will bring you up to date on current concepts in cystic fibrosis care.

Learning Objectives
At the completion of this activity, pharmacists will be able to:

1. Explain the basic pathophysiology of cystic fibrosis (CF) and the evolution of treatment advances that increased median life expectancy from early childhood to nearly 50 years of age.
2. Discuss the latest data regarding therapies and care guidelines for CF.
3. Identify current challenges and gaps regarding available CF therapies including adherence, off-label use, and special populations.

Speaker
Dan Clauw, MD
Director, Chronic Pain and Fatigue Research Center
Professor of Anesthesiology, Internal Medicine, and Psychiatry
University of Michigan
Ann Arbor, Michigan

ACPE Universal Activity Number 0112-9999-21-420-L08-P
1.0 contact hour (0.1 CEU)
Knowledge-based

Needs Assessment
Disorders distinguished by symptoms of chronic pain and fatigue—systemic conditions and regional pain syndromes such as fibromyalgia, interstitial cystitis, osteoarthritis, and low back pain—all have common pathogenic and clinical features.  One of those features is “pain centralization,” which occurs when the central nervous system doesn’t process pain signals properly.  Pain that starts in the body (peripheral pain) is amplified in the brain; patients may feel pain more strongly, and their ability to tolerate pain may be decreased.  This type of pain is unlikely to respond to usual treatment strategies and requires a shift in thinking about what constitutes “pain management.”  This session will explore the underlying mechanisms of pain centralization and discuss potential roles for nonpharmacologic therapies and non-opioid analgesics.

Learning Objectives
At the completion of this activity, pharmacists will be able to:

1. Describe the pain phenomenon known as centralization
2. Discuss the importance of managing chronic pain based on the underlying mechanism rather than the disease.
3. Identify pharmacological and nonpharmacological treatments that are likely to be of greatest benefit for chronic pain.